HUMAN FETAL TISSUE – Adds to existing law to establish provisions regarding the use of human fetal tissue in products.
S1310, the Human Fetal Tissue Transparency Act, would require disclosure on products sold in Idaho if they contain, were developed using, or were tested with human fetal tissue, embryonic cells, or derivative biological matter such as fetal DNA. The bill is framed as a consumer transparency measure, intended to help purchasers make informed choices based on personal, ethical, or moral beliefs. It also creates a civil enforcement framework and includes protections for retailers who act in good faith.
The bill would add new labeling and disclosure requirements to Idaho law for certain consumer products and would apply not only to products directly containing these materials, but also to products whose production lots or final products were tested using them. According to the fiscal note, it is not expected to require state spending or have a fiscal impact on the general fund. The bill was introduced and referred to the Commerce & Human Resources Committee, but no votes or committee hearing transcript were provided in the available record.
Overall sentiment in the available materials appears supportive from the sponsor’s perspective, with the bill presented as a transparency and consumer-choice measure rather than a punitive regulation. Because there are no recorded committee discussions or votes in the provided context, there is no documented opposition or broader legislative sentiment to assess from the record.
The main point of contention likely concerns the scope and practicality of the disclosure requirement, especially for products that were only indirectly associated with fetal tissue or embryonic-cell testing. Potential concerns may include compliance burdens for manufacturers and retailers, the difficulty of tracing testing history through supply chains, and whether the labeling requirement could affect products beyond the bill’s stated consumer-protection purpose. Supporters, by contrast, would emphasize informed consent in purchasing and alignment with ethical or religious values.
The bill would amend Idaho law to create a new product-disclosure regime for items associated with human fetal tissue, embryonic cells, or related biological derivatives. It would affect manufacturers, distributors, and retailers selling covered products in Idaho by requiring labeling or disclosure and by establishing civil enforcement provisions, while also providing a good-faith defense or protection for retailers. The measure is designed to operate without state appropriations or direct fiscal cost.
Based on the bill text and sponsor materials, the bill is presented in a strongly favorable light as a consumer transparency and values-based purchasing measure. No committee transcript or vote record is available in the provided materials, so there is no documented legislative debate to indicate broader support or opposition. The available record therefore suggests a proponent-driven, low-conflict framing, with sentiment centered on disclosure and consumer choice.
The likely areas of contention are the breadth of the labeling mandate and the feasibility of compliance. Critics could argue that requiring disclosure for products merely tested with fetal tissue or embryonic cells may be difficult to verify, could impose burdens on supply chains, and may reach products far removed from any direct use of such materials. Supporters would likely contend that the bill is narrowly aimed at transparency and allows consumers to avoid products inconsistent with their ethical, moral, or religious beliefs.